| 28 April 2010 - Ergomed announces continued growth of its Dubai operations |
 |
|
Dubai, UAE - 28 April 2010 As the first international Contract Research Organization to set-up at the Dubai Biotechnology and Research Park (DuBiotech) in the UAE, Ergomed Clinical Research has successfully established in the past two years a strong presence as one of the leading CROs in the Middle East and North Africa (MENA) region. "We are very strongly positioned to cater to the Pharma and Biotech companies looking to access a large patient population in an environment that provides well defined regulations and well established healthcare facilities such as the MENA region" commented Dr. Miroslav Reljanovic, CEO of Ergomed Group. With a solid local infrastructure centered in Dubai, strong support from the European operational team and an understanding of the regional regulatory and socio-cultural requirements, Ergomed has gained an excellent reputation as a regional CRO through managing multiple studies ranging from Phase II regulatory trials to Phase IV post-marketing trials for local and international clients. Ergomed is basing its approach on its 13-year experience in establishing clinical development businesses in emerging markets. The Ergomed MENA operations follow the highly efficient dual-model of clinical trials management which incorporates project management and study site management as the main components. The year 2010 holds multiple expansion opportunities for Ergomed in the MENA region and promises to be a successful year with many projects in the pipeline. Ergomed will also continue its efforts to support the growth of the clinical research industry in the region through working closely with the regulators and supporting major conferences. "Ergomed will take part in the Pharmaceutical and Biotechnology Middle East (PABME 2010) conference again this year as an exhibitor and sponsor. We believe in the importance of the networking and educational opportunities that such venues offer and their role in providing exposure of the region's capabilities to the rest of the world" commented Dr. Rania Al-Shami, Director of Business Development at Ergomed and member of the PABME advisory committee. Ergomed will also be participating in additional international conferences representing the clinical research industry in the MENA region highlighting the potential for running successful trials in the region. The team will be present at the BIO 2010 conference taking place in Chicago from May 23-25, 2010. Ergomed will be exhibiting at the DuBiotech stand thus showing our clear commitment to working closely with the key regional players in healthcare research and drug development. Contact details:
About Ergomed ERGOMED is a specialized international clinical development company offering contract clinical research and co-development partnerships to biotechnology and pharmaceutical companies worldwide in the fields of neurology, oncology and immunology. Ergomed's approach to clinical research ensures effective patient recruitment, reducing the time and costs of clinical trials and complementing the drug discovery capabilities of its customers and partners. The Company has a dual business model offering standard clinical trial management contracts and also co-development partnerships to share the risks and rewards of clinical development. Ergomed is headquartered in Frankfurt, Germany, and also has offices in UK, UAE, Russia, Croatia, Poland, Spain, Serbia and the USA. |